Journal
JOURNAL OF IMMUNOLOGY
Volume 182, Issue 3, Pages 1260-1269Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.182.3.1260
Keywords
-
Categories
Funding
- New Zealand Health Research Council
- Cancer Society of New Zealand,
- Wellington Medical Research Foundation
- Genesis Oncology Trust
- Erwin Schroedinger Auslandsstipendium [FWFJ2479]
- Austrian Science Fund
- New Zealand Health Research Council Sir Charles Hercus Fellowship
Ask authors/readers for more resources
An efficient pathway of cross-presentation common to a range of dendritic cell (DC) populations was identified by targeting Ag to MHC class II molecules. This finding was achieved by conjugating Ag to M1, which is a modified version of the superantigen streptococcal mitogenic exotoxin Z-2 that binds to MHC class II molecules but cannot directly stimulate T cells. M1 conjugates were efficiently presented to CD4(+) and CD8(+) T cells by bone marrow-derived DC and Langerhans cells in vitro. Whereas nonconjugated Ag was preferentially cross-presented by splenic CD8 alpha(+) DC in vivo, M1-conjugated Ag was cross-presented by all dendritic subtypes assessed. Potent effector T cell responses with antitumor activity were elicited when M1 conjugates were injected together with an adjuvant. This method of Ag delivery has significant potential in therapeutic applications. The Journal of Immunology, 2009, 182: 1260-1269.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available